TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06395389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HealthEdu)
Description: The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values in Action (VIA)
Description: VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
Study: NCT05951959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Investigator Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Investigator Product
Study: NCT06236711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
Study: NCT05967624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
Study: NCT06566755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104) combined with chemotherapy and bevacizumab
Description: Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W.
Study: NCT06640023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Intervention
Description: For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
Study: NCT04856319

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
Study: NCT06165003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of broselow tape
Description: In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses.
Study: NCT06640023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Intervention
Description: For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountable Justification
Description: For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the After Visit Summary.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display.
Study: NCT05130567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-128 capsules
Description: Oral dosing with LP-128 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-128 capsules
Description: Oral dosing with LP-128 capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match LP-128 capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match LP-128 capsules.
Study: NCT05387759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Supratherapeutic Dose
Description: Aticaprant supratherapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Supratherapeutic Dose
Description: Aticaprant supratherapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Supratherapeutic Dose
Description: Aticaprant supratherapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Supratherapeutic Dose
Description: Aticaprant supratherapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Therapeutic Dose
Description: Aticaprant therapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Therapeutic Dose
Description: Aticaprant therapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Therapeutic Dose
Description: Aticaprant therapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant Therapeutic Dose
Description: Aticaprant therapeutic dose capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06640023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountable Justification
Description: For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the After Visit Summary.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display.
Study: NCT06181136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL126
Description: intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL126
Description: intravenous repeating dose
Study: NCT05387759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin capsule will be administered orally.
Study: NCT06181136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL126
Description: intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL126
Description: intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL126
Description: intravenous repeating dose
Study: NCT05387759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin capsule will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin capsule will be administered orally.
Study: NCT04705077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: 2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: 2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
Study: NCT05460624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg-containing breakfast
Description: Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.

Intervention type: OTHER
Group type: OTHER
Intervention: Typical American-style breakfast excluding eggs
Description: Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
Study: NCT05393310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation
Description: The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWM group
Description: MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
Study: NCT05389592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active tDCS and cognitive training
Description: Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS and cognitive training
Description: Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
Study: NCT05676242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day
Study: NCT04805905

Intervention type: OTHER
Intervention: FACE-Q patient reported outcome
Description: As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment.

Intervention type: OTHER
Intervention: FACE-Q patient reported outcome
Description: As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment.
Study: NCT05077254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine 2023-2024
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine 2023-2024
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine 2023-2024
Description: Administration: One dose administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna COVID-19 Vaccine 2023-2024
Description: Administration: One dose administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC IS Regimen
Description: Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC IS Regimen
Description: Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC IS Reduction
Description: Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC IS Reduction
Description: Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
Study: NCT05438953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)
Description: Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)
Description: Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
Study: NCT06532903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective muscle electrostimulation with exponential current
Description: An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial muscle reeducation in front of the mirror
Description: Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done.
Study: NCT04879303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted social skill intervention
Description: Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human-only instruction programme on social skill training
Description: The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
Study: NCT04868201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0-anxiety
Description: 0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
Study: NCT05987891

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill exercise stress test
Description: Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
Study: NCT05257265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine Hydrochloride
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine Hydrochloride
Description: Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT05673720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS paired with active MBM
Description: Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS paired with sham MBM
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
Study: NCT04901884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/MR with 18F-FDG
Description: (18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
Study: NCT04856696

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PGT-A
Description: trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGT-A
Description: trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: non-invasive PGT-A
Description: cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: non-invasive PGT-A
Description: cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
Study: NCT04740606

Intervention type: DEVICE
Intervention: Augmented Reality Navigation System
Description: Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.